Novartis (NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma met its primary endpoint in ...

Mydicar is under clinical development by Sardocor and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% phase transition ...

BASEL, Switzerland I 30, 2024 I Novartis today announced positive topline results from the Phase III STEER study. This pivotal study assessed the ...

Pfizer has decided to buy a company developing a technology based around advanced recombinant Adeno-Associated Virus (rAAV) vector. None of these platforms are yet proven as therapies and all ...

Novartis intrathecal onasemnogene abeparvovec phase III STEER study meets primary endpoint in children and young adults with SMA: Basel Tuesday, December 31, 2024, 11:00 Hrs [IST] ...

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onase ...